BENTSUR RON
SEC CIK 1251213 · EDGAR
BoughtSold
Most active insiders at NVCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mosseri Marlio Charles | 10% | $1.87M | — |
| 2 | BENTSUR RON | COB, CEO, Dir, 10% | $278.6K | — |
| 3 | Sanchez Juan | Dir | $75.3K | — |
| 4 | Kaplan Matthew L. | Dir | $64.2K | — |
| 5 | Poradosu Enrique | Chief Science, Business Off | — | — |
| 6 | Carson Michael J. | VP, Fin | — | — |
| 7 | Shemesh Shay | Chief Dev, Ops. Off | — | — |
| 8 | Hoberman Kenneth | Dir | — | — |
| 9 | Oliviero James F III | Dir | — | — |
Transactions 56
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 13:39 | 2026-06-30 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $20.00 | +12.5K | 3.69M | +0.3% | +$250.0K | |
| 2026-01-09 | 2026-01-06 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | A - Grant | $0.00 | +150.0K | 3.68M | +4% | $0 | |
| 2025-11-06 | 2025-11-05 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $5.72 | +5,000 | 3.53M | +0.1% | +$28.6K | |
| 2025-01-03 | 2025-01-02 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | A - Grant | $0.00 | +250.0K | 3.52M | +8% | $0 | |
| 2024-12-26 | 2024-12-24 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $4.65 | +4,500 | 3.27M | +0.1% | +$20.9K | |
| 2024-11-18 | 2024-11-15 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $4.92 | +20.0K | 3.27M | +0.6% | +$98.4K | |
| 2024-05-15 | 2024-05-14 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $6.74 | +1,940 | 3.25M | +0.1% | +$13.1K | |
| 2024-05-13 | 2024-05-10 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $6.40 | +2,000 | 3.24M | +0.1% | +$12.8K | |
| 2024-03-19 | 2024-03-18 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $10.29 | +5,000 | 3.24M | +0.2% | +$51.4K | |
| 2023-10-12 | 2023-10-10 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $11.08 | +640 | 3.24M | +0.0% | +$7,091 | |
| M | 2023-10-10 | 2023-10-06+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $11.21 | +1,080 | 3.24M | +0.0% | +$12.1K |
| M | 2023-10-06 | 2023-10-04+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $11.01 | +3,220 | 3.23M | +0.1% | +$35.5K |
| M | 2023-08-16 | 2023-08-15+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $14.61 | +350 | 3.23M | +0.0% | +$5,112 |
| M | 2023-08-11 | 2023-08-08+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $14.73 | +300 | 3.23M | +0.0% | +$4,418 |
| M | 2023-07-24 | 2023-07-20+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $14.92 | +335 | 3.23M | +0.0% | +$4,998 |
| 2023-07-20 | 2023-07-19 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $14.33 | +200 | 3.23M | +0.0% | +$2,866 | |
| M | 2023-07-18 | 2023-07-07+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $15.52 | +260 | 3.23M | +0.0% | +$4,035 |
| 2023-07-07 | 2023-07-06 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $14.88 | +320 | 3.23M | +0.0% | +$4,762 | |
| 2023-06-27 | 2023-06-26 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $16.50 | +750 | 3.23M | +0.0% | +$12.4K | |
| 2023-06-22 | 2023-06-21 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $17.88 | +500 | 3.23M | +0.0% | +$8,940 | |
| M | 2023-06-08 | 2023-06-07+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $17.45 | +350 | 3.23M | +0.0% | +$6,108 |
| 2023-06-01 | 2023-05-31 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $17.28 | +330 | 3.23M | +0.0% | +$5,702 | |
| 2023-05-26 | 2023-05-24 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $17.49 | +200 | 3.23M | +0.0% | +$3,498 | |
| 2023-05-18 | 2023-05-16 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $17.03 | +320 | 3.23M | +0.0% | +$5,450 | |
| 2023-03-27 | 2023-03-23 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $12.13 | +230 | 3.23M | +0.0% | +$2,790 | |
| 2023-03-23 | 2023-03-21 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $12.08 | +480 | 3.23M | +0.0% | +$5,798 | |
| 2023-03-21 | 2023-03-20 | XAIR | Beyond Air, Inc. | BENTSUR RON | Dir | P - Purchase | $6.48 | +2,300 | 144.7K | +2% | +$14.9K | |
| M | 2023-03-16 | 2023-03-14+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $10.86 | +2,160 | 3.23M | +0.1% | +$23.5K |
| 2023-01-13 | 2023-01-12 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | A - Grant | $0.00 | +210.0K | 3.23M | +7% | $0 | |
| 2022-11-30 | 2022-11-30 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.45 | +150 | 3.02M | +0.0% | +$1,118 | |
| M | 2022-11-29 | 2022-11-25+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.41 | +450 | 3.02M | +0.0% | +$3,334 |
| M | 2022-11-21 | 2022-11-17+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.23 | +750 | 3.01M | +0.0% | +$5,425 |
| 2022-11-16 | 2022-11-10 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.07 | +1,000 | 3.01M | +0.0% | +$7,070 | |
| M | 2022-10-03 | 2022-09-28+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.34 | +1,000 | 3.01M | +0.0% | +$7,345 |
| M | 2022-09-27 | 2022-09-23+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.85 | +1,500 | 3.01M | +0.0% | +$11.8K |
| M | 2022-09-06 | 2022-09-01+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $8.29 | +1,700 | 3.01M | +0.1% | +$14.1K |
| M | 2022-08-30 | 2022-08-23+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $9.05 | +1,500 | 3.01M | +0.0% | +$13.6K |
| M | 2022-08-22 | 2022-08-18+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $8.69 | +19.4K | 3.01M | +0.7% | +$168.7K |
| 2022-08-16 | 2022-08-11 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $8.40 | +19.7K | 2.99M | +0.7% | +$165.2K | |
| 2022-07-05 | 2022-06-30 | XAIR | Beyond Air, Inc. | BENTSUR RON | Dir | S - Sale | $6.53 | -40.0K | 142.4K | -22% | -$261.2K | |
| M | 2022-06-30 | 2022-06-28+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $11.63 | +4,000 | 2.96M | +0.1% | +$46.5K |
| M | 2022-06-27 | 2022-06-22+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $12.09 | +700 | 2.96M | +0.0% | +$8,462 |
| M | 2022-05-31 | 2022-05-26+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $15.82 | +1,000 | 2.96M | +0.0% | +$15.8K |
| M | 2022-05-23 | 2022-05-19+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $16.73 | +1,200 | 2.96M | +0.0% | +$20.1K |
| M | 2022-05-19 | 2022-05-17+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $19.48 | +2,010 | 2.96M | +0.1% | +$39.2K |
| M | 2022-05-17 | 2022-05-13+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $18.82 | +1,700 | 2.96M | +0.1% | +$32.0K |
| M | 2022-05-13 | 2022-05-12 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $16.99 | +12.2K | 2.95M | +0.4% | +$208.0K |
| 2022-04-05 | 2022-04-01 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | A - Grant | $0.00 | +120.0K | 2.95M | +4% | $0 | |
| 2022-03-29 | 2022-03-28 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.05 | +4,000 | 2.83M | +0.1% | +$28.2K | |
| 2022-03-18 | 2022-03-17 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $7.63 | +7,000 | 2.82M | +0.2% | +$53.4K | |
| 2022-02-15 | 2022-02-14 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir | P - Purchase | $5.88 | +8,000 | 2.81M | +0.3% | +$47.0K | |
| 2022-02-11 | 2022-02-10 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir | P - Purchase | $6.34 | +8,500 | 2.81M | +0.3% | +$53.9K | |
| M | 2022-02-08 | 2022-02-04+ | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | COB, CEO, Dir | P - Purchase | $4.96 | +232.5K | 2.78M | +9% | +$1.15M |
| M | 2021-11-26 | 2021-11-24 | XAIR | Beyond Air, Inc. | BENTSUR RON | Dir | S - Sale | $13.53 | -37.5K | 182.4K | -17% | -$507.1K |
| D | 2021-11-24 | 2021-11-22 | XAIR | Beyond Air, Inc. | BENTSUR RON | Dir | M - OptEx | $3.66 | +50.0K | 232.4K | +27% | +$183.0K |
| D | 2021-11-24 | 2021-11-22 | XAIR | Beyond Air, Inc. | BENTSUR RON | Dir | F - Tax | $14.60 | -12.5K | 219.9K | -5% | -$183.0K |
Purchase Sale Sale after option exercise All abbreviations